Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16344889 | 1.00 | KMT2A (0.42) | KMT2AALDH1A1PTGS2KEAP1NFE2L2 | |
| SCHEMBL8661856 | 0.83 | KEAP1 (0.43) | KMT2AALDH1A1PTGS2KEAP1NFE2L2 | |
| SCHEMBL14650777 | 0.82 | GAA (0.37) | KMT2AALDH1A1PTGS2KEAP1NFE2L2 | |
| SCHEMBL32681940 | 0.81 | KMT2A (0.44) | KMT2AALDH1A1PTGS2KEAP1NFE2L2 | |
| SCHEMBL22440088 | 0.81 | KMT2A (0.44) | KMT2AALDH1A1PTGS2KEAP1NFE2L2 | |
| SCHEMBL1307914 | 0.78 | SLC6A3 (0.44) | KMT2AALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL1193499 | 0.78 | SLC6A3 (0.44) | KMT2AALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL506978 | 0.78 | SLC6A3 (0.44) | KMT2AALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL14650775 | 0.77 | APLNR (0.48) | ALDH1A1KEAP1NFE2L2VDRGAA | |
| SCHEMBL22470485 | 0.77 | TSHR (0.42) | KMT2AALDH1A1PTGS2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | KMT2A 832/4885ALDH1A1 1320/4885PTGS2 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.